Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Vincristine is an effective therapeutic approach for transplantation-associated thrombotic microangiopathy

Bone Marrow Transplantation volume 37, pages 337–338 (2006)Cite this article

Transplantation-associated thrombotic microangiopathy (TA-TMA) is a severe complication which affects 5–74% of patients undergoing allogeneic HSCT.1 Risk factors for TA-TMA include the use of high doses of radio- and chemotherapy, infections, GVHD, and the use of cyclosporine (CsA) or tacrolimus.1, 2

There is no consensus on the most appropriate treatment for patients with TA-TMA. The role of plasma exchange (PE) is controversial3 since response rates are considerably lower than in patients with thrombotic thrombocytopenic purpura (TTP). Thus, many patients require additional therapeutic strategies such as protein A immunoadsorption, splenectomy, nitric oxide, defibrotide, and immunosuppressive agents such as vincristine or steroids.4, 5, 6

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Daly AS, Hasegawa WS, Lipton H, Messner HA, Kiss TL . Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venooclusive disease of the liver. Transfus Apher Sci 2002; 27: 3–12.

    Article  Google Scholar 

  2. Fuge R, Bird J, Fraser A, Hart D, Hunt L, Cornish J et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura ocurring after bone marrow transplantation. Br J Haematol 2001; 113: 58–64.

    Article  CAS  Google Scholar 

  3. Llamas P, Romero R, Cabrera R, Sanjuan I, Forés R, Fernandez MN . Management of thrombotic microangiopathy following allogenic transplantation: what is the role of plasma exchange? Bone Marrow Transplant 1997; 20: 305–306.

    Article  CAS  Google Scholar 

  4. Daly AS, Xenocostas A, Lipton JH . Transplantation-associated thrombotic microangiopathy: twenty-two years later. Bone Marrow Transplant 2002; 30: 709–715.

    Article  CAS  Google Scholar 

  5. Silva VA, Frei-Lahr D, Brown RA, Herzig GP . Plasma exchange and vincristine in the treatment of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura associated with bone marrow transplantation. J Clin Apher 1991; 6: 16–20.

    Article  CAS  Google Scholar 

  6. Böhm M, Betz C, Miesbach W, Krause M, Von Auer C, Geiger H et al. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol 2005; 129: 644–652.

    Article  Google Scholar 

  7. Zeigler ZR, Shadduck RK, Nemunaitis J, Andrews DF, Rosenfeld CS . Bone marrow transplant-associated thrombotic microangiopathy: a case series. Bone Marrow Transplant 1995; 15: 247–253.

    CAS  PubMed  Google Scholar 

  8. Mayer S, Aledort L . Thrombotic microangiopathy: differential diagnosis, pathophysiology and therapeutic strategies. Mount sinayi J Med 2005; 72: 166–175.

    Google Scholar 

  9. Ziman A, Mitri M, Klapper E, Pepkowitz SH, Goldfinger D . Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution’s experience and review of the literature. Transfus pract 2005; 45: 41–49.

    Article  CAS  Google Scholar 

  10. Ferrara F, Annunziata M, Pollio F, Palmieri S, Copia C, Mele G et al. Vincristine as treatment for recurrent episodes of thrombotic thrombocytopenic purpura. Am J Hematol 2002; 81: 7–10.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Hematología, Hospital Clínico Universitario de Salamanca, Paseo de San Vicente s/n, Salamanca, 37007, Spain

    J Mateos, J A Pérez-Simón, D Caballero, C Castilla, O Lopez, E Perez, C Cañizo, L Vazquez & J F San Miguel

  2. Centro de Investigación del Cáncer, Universidad de Salamanca, Salamanca, 37007, Spain

    J A Pérez-Simón, C Cañizo & J F San Miguel

Authors
  1. J Mateos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J A Pérez-Simón
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Caballero
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Castilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O Lopez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E Perez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Cañizo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L Vazquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J F San Miguel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mateos, J., Pérez-Simón, J., Caballero, D. et al. Vincristine is an effective therapeutic approach for transplantation-associated thrombotic microangiopathy. Bone Marrow Transplant 37, 337–338 (2006). https://doi.org/10.1038/sj.bmt.1705241

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705241

Search

Advanced search

Quick links